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Abstract
Background: The high co-morbidity of mental disorders, particularly depression, with non-communicable diseases
(NCDs) such as cardiovascular disease (CVD), is concerning given the rising burden of NCDs globally, and the role
depression plays in confounding prevention and treatment of NCDs. The objective of this randomised control trial
(RCT) is to determine the real-world effectiveness of strengthened depression identification and management on
depression outcomes in hypertensive patients attending primary health care (PHC) facilities in South Africa (SA).
Methods/design: The study design is a pragmatic, two-arm, parallel-cluster RCT, the unit of randomisation being
the clinics, with outcomes being measured for individual participants. The 20 largest eligible clinics from one district
in the North West Province are enrolled in the trial. Equal numbers of hypertensive patients (n = 50) identified as
having depression using the Patient Health Questionnaire (PHQ-9) are enrolled from each clinic, making up a total
of 1000 participants with 500 in each arm. The nurse clinicians in the control facilities receive the standard training
in Primary Care 101 (PC101), a clinical decision support tool for integrated chronic care that includes guidelines for
hypertension and depression care. Referral pathways available include referrals to PHC physicians, clinical or counselling
psychologists and outpatient psychiatric and psychological services. In the intervention clinics, this training is supplemented
with strengthened training in the depression components of PC101 as well as training in clinical communication skills for
nurse-led chronic care. Referral pathways are strengthened through the introduction of a facility-based behavioural health
counsellor, trained to provide structured manualised counselling for depression and adherence counselling for all chronic
conditions. The primary outcome is defined as at least 50% reduction in PHQ-9 score measured at 6 months.
Discussion: This trial should provide evidence of the real world effectiveness of strengtheneddepression identification and
collaborative management on health outcomes of hypertensive patients withcomorbid depression attending PHC facilities
in South Africa.
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Background
Burden and significance of co-morbid depression in
patients with hypertension
Cardiovascular disease (CVD) (including coronary heart
disease (CHD), hypertension and stroke) is the leading
cause of mortality in the world [1]. Even in contexts
such as South Africa, which has a large human immuno-
deficiency virus (HIV) burden, CVD is among the top
three causes of years of life lost (YLLs) [2]. In relation to
disability-adjusted life years (DALYs), which include
quantification of YLLs and years lived with disability
(YLD), data from South Africa shows a rapid rise in
NCDs [2]. Estimates by the World Health Organisation
(WHO) using DALYs suggest that NCDs were respon-
sible for 28% of the total burden of disease in South
Africa in 2004 [3]. These conditions are becoming more
prevalent with the diffusion of urban lifestyle risk
factors, including tobacco smoking, unhealthy diet,
alcohol consumption and physical inactivity [4–6].
The prevalence of hypertension, at 20% of the adult
population, is of particular concern [7], with CVD pro-
jected to increase by over 40% in the 35–65 years age
group by 2030 [6]. A survey of over 18,000 encounters
showed that hypertension follow-up was the leading
reason for attending primary care clinics, accounting for
10% of all consultations among adults [8]. Similarly, in a
study at a primary care clinic in Khayelitsha, Cape
Town, hypertension was the most common morbidity
(65%) among 14,364 adult chronic disease patients with
tuberculosis (TB), HIV, diabetes or hypertension [9].
NCDs often co-exist with one another, as well as with
mental disorders. Results from 245,404 participants from
the World Health Surveys in 60 countries revealed that
co-morbid depression was present in respondents with
diabetes (9.3%), arthritis (10.7%), angina (15%) and
asthma (18.1%) [10]. Prevalence rates of depression were
highest when there was co-morbidity of two or more
chronic physical conditions (23%). Relatively high rates
of co-morbidity of NCDs are increasingly being reported
in patients in South Africa [11], with a local study also
revealing a similar pattern where multiple co-
morbidities were associated with increased psychological
symptoms [12].
Prevalence of depression in respondents from the
World Health Surveys without chronic diseases on the
other hand was less than 5% [13]. This suggests that
people with NCDs are two to five times more likely to
suffer from depression than those without NCDs, with
the likelihood increasing with multiple co-morbidities.
Depression co-existing with other NCDs was also shown
to result in greater health decrements than when one or
more physical conditions were present [10]. Mental
disorders have a mutually reinforcing relationship with
NCDs [14], compromising both prevention and treat-
ment through exacerbating modifiable risk factors, and
by compromising adherence and self-care, respectively
[15]. In addition, through compromising the endocrine
and immune systems, depression and anxiety can have a
negative interactive effect at the biological level, exacerbat-
ing vulnerability to, and the course of, existing NCDs [16].
With respect to CVD in particular, co-morbid depression
increases the risk of CHD and stroke [17–24]. Risk factors
for CHD and stroke are related to unhealthy lifestyles
which are more common among people with depression or
chronic ill-health. Depressed people are more likely to
smoke and less likely to exercise, adhere to chronic medica-
tion, or eat healthily [25, 26]. It is also possible that there
are common causal physiological pathways, such as inflam-
mation, which underlie both CVD and depression [16].
With regard to the impact of common mental disorders on
adherence in hypertensive patients specifically, some
studies from high-income countries (HICs) show higher
non-adherence in patients with co-morbid depression [27].
However, it should be noted that a recent study in Ghana
found that there was no relationship between co-morbid
depression and/or anxiety and non-adherence, although
they did find a relationship between moderate to severe
stress symptoms and non-adherence [28].
Health system reforms to accommodate the rise in
co-existing chronic conditions
In response to the rising burden of co-existing chronic dis-
eases that includes HIV, TB and NCDs, the South African
National Department of Health has piloted a multi-disease,
integrated, chronic services approach [29]. Care for chronic
conditions requires collaborative care, which extends
beyond the biomedical model that characterises acute care,
to incorporate the following elements: self-management
support and access to behavioural-change programmes (to
help patients have control over their illness and live with
their condition); clinical decision support (to improve
providers’ expertise and skills to provide the most
evidence-informed care); clinical information systems (cap-
turing patient-level information that will help clinical care
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and follow-up); delivery system design to promote chronic
care (promoting planned team-based care and identifying
the roles and responsibilities of the different members of
the health care team so that they can work synergistically);
linkages to community resources such as support groups;
and quality improvement to improve the organisation of
health care as a whole [30–32].
Such integrated collaborative care for clusters of co-
existing illnesses described above, especially physical and
mental disorders, has been shown to be more effective
than usual care in HICs. Exemplary evidence of this is
provided by the TEAMcare trial in the United States
which targeted patients with depression and poorly con-
trolled diabetes, heart disease or both, using nurse-led,
multi-disease collaborative care [33]. The TEAMcare
intervention combined pharmacotherapy with psycho-
social interventions, supported by self-help materials, to
assist patients to solve problems and set goals to improve
adherence and self-care.
In South Africa, at the facility level, the integrated
chronic care approach which is part of the integrated
clinical management service, aims to strengthen the
quality of care for chronic conditions through, inter alia:
(1) facility re-organisation to improve the quality of care
and servicing all chronic care patients at one service
point and (2) strengthening clinical decision support
through onsite in-service training using an integrated set
of algorithms and checklists developed to support nurse-
led identification and management of all common
chronic diseases whether communicable, NCDs or mental
illness – called PC101 [34]. At the community level, well-
controlled patients are supported to engage in self-
management by community health worker (CHW)-driven,
ward-based outreach teams (WBOTs), which are part of
the primary health care (PHC) re-engineering framework
in South Africa. At a population level, health promotion
and population screening is envisaged to promote an
informed and activated population [35].
While mental health problems managed at the PHC
level are included in the basket of chronic disease
categories catered for by this integrated approach, find-
ings suggest that the limited mental health component
included in the basic PC101 training is insufficient to
improve PHC nurses’ knowledge of mental health condi-
tions [36], and was not associated with increased case
detection of depression in a previous trial focussing on
NCDs [37]. There is thus a need to strengthen the mental
health component of this integrated approach in order to
close the large treatment gap for mental disorders in
South Africa, particularly in the chronic care population.
While one in six adults experience a common mental
disorder (depression, anxiety disorders and substance use
disorders) over a 12-month period [38], only one in four
receives treatment of any kind [39].
The Programme for improving mental health care
(PRIME) [40] in South Africa has been working in one
of the districts where this integrated model has been
piloted for the past 5 years to develop and evaluate the
feasibility of an integrated collaborative-care package for
depression and alcohol use disorders (AUD). The package
includes strengthening of the mental health component of
PC101 training and referral pathways for management of
AUD and depression [41]; the use of lay behavioural
health counsellors to provide manual-based counselling
for chronic care patients with depression, shown to have
promising outcomes in a pilot trial [42]; strengthened
referral pathways for initiation of psychotropic medication
by primary health care physicians; as well as referral to
mental health specialists for more severe and treatment
resistant depression. In addition, systems strengthening
innovations to support these efforts have been introduced
through the EMERALD (Emerging Mental Health
Systems in Low- and Middle-income Countries (LIMCs))
programme [43], including clinical communication skills
for nurse-led chronic care and a strengthened employee
assistance programme for primary health care providers
experiencing personal problems and burn-out.
Development of the strengthened mental health inter-
vention has been iterative, guided by the United King-
dom (UK) Medical Research Council (MRC) framework
for the development of complex interventions [44] and
refined during two successive pilots, the first in a single
clinic, and the second in a further three clinics. The
resultant intervention has been scaled up to 10 clinics in
the Dr. Kenneth Kaunda (DKK) District and a further 10
clinics in the adjacent Bojanala Platinum (BP) District
during the period 2014–2017. The intervention targets
depression co-morbid with all common chronic condi-
tions managed at primary care facilities.
This paper describes one of a pair of trials evaluating
the effects of this intervention on mental and physical
outcomes among chronic care patients. The other trial
(Co-morbid Affective Disorders, HIV and Long-term
Health – CobALT), focusses on chronically ill patients
receiving antiretroviral (ART) treatment. These two con-
ditions covered by this pair of trials account for most
chronic care attendances in South Africa. Similarities
and differences between the two trials are described in
Table 1. The main distinction is the restriction of the
trial reported in this paper to one of these districts, the
eligibility criteria for patient participants and the choice
of physical outcomes.
Objectives
The primary objective of the trial is to determine the real-
world effectiveness of strengthened integrated depression
care among patients with co-existing hypertension, in a
district where the integrated chronic care approach is
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being piloted. The primary hypothesis of the trial is that
patients attending intervention facilities will demonstrate
improved depression outcomes, as defined by a 50%
reduction in depressive symptoms measured on the
Patient Health Questionnaire (PHQ-9) at 6 months post
baseline, compared to patients who attend clinics where
the strengthened mental health component has not been
added to the existing services.
As one of the secondary outcomes, we will determine
the impact of the intervention on physical outcomes for
hypertension as the trial was under-powered to have this
as a primary outcome. We hypothesise that patients
attending intervention facilities will demonstrate reduc-
tions in their blood pressure at 6 and 12 months post
baseline, compared to patients who attend control
clinics. Other secondary outcomes for the trial are listed
under the ‘Outcome measures’ section.
Funding and all administrative information required
by the Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) Checklist [45] including
the structure, function and composition of all the trial
committees, are summarised in the administrative files
supplied as Additional files 1 and 2 of the web-based
supplementary files (see Additional file 1 for details,
Additional file 2 for the SPIRIT Checklist and Fig. 1 for
the SPIRIT Figure). The trial is funded from the UK
Department of International Development (DFID)
through PRIME, supported through grant agreement
HRPC10. The funder did not contribute to the study
design, data collection and management and will not
contribute to data analysis, interpretation, write-up or
decisions to submit the results for publication.
Methods/design
Trial design
The study design is a pragmatic, two-arm, parallel-cluster
randomised controlled trial (RCT) stratified by sub-district.
The unit of randomisation is the clinics, and we measure
outcomes on individual participants.
Setting
The study site is the DKK District in the North West
Province of South Africa located adjacent to and west of
Table 1 Comparison of the pair of trials evaluating the intervention developed during PRIME-SA
Characteristic PRIME (PRogramme for Improving Mental health
carE-SA) trial
CobALT (Co-morbid Affective Disorders and Long-term
Health) trial
Setting Dr. Kenneth Kaunda District, North West Province,
South Africa
Dr. Kenneth Kaunda and Bojanala Districts, North West
Province, South Africa
Clinic participants 20 primary care clinics 40 primary care clinics
Patient participants Patients 18 years or older attending for hypertension
treatment with a Patient Health Questionnaire score
of 9 or more (n = 1000, 50 per clinic)
Patients 18 years or older attending for antiretroviral
therapy (ART) with a Patient Health Questionnaire
score of 9 or more (n = 2000, 50 per clinic)
Number and unit
of randomisation
20 primary care clinics 40 primary care clinics
Trial participants Patients 18 years or older attending for hypertension
treatment with a Patient Health Questionnaire score
of 9 or more (n = 1000, 50 per clinic)
Patients 18 years or older attending for ART with a
Patient Health Questionnaire score of 9 or more
(n = 2000, 50 per clinic)
Control arm The Integrated Services Delivery Model which includes
distribution and training in the PC101 guide
Same
Intervention arm Three additional elements:
1. Clinical communications skills training for nurse clinicians
2. Supplementary training in the mental health components of PC101
3. Clinic-based behaviour-change counsellors equipped
to provide morning talks on mental health to promote
mental health literacy, manualised counselling for
depression (8 sessions, individual or group) and
adherence counselling (individual)
Same
Primary mental
health outcome
Response at 6 months, defined as a 50% improvement
from baseline in the Patient Health Questionnaire 9 score
Same
Primary clinical
health outcome
Not applicable Viral load suppression at 12 months
Duration of fieldwork April 2015 to December 2016 April 2015 to December 2017
Controlled Trials
Registration Number
NCT02425124 NCT02407691
Funding UK Department for International Development National Institutes of Mental Health, United States
of America
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the populous Gauteng region (see Fig. 2). The South
African National Department of Health guided selection
of the site as it is a priority district for several initiatives
to strengthen primary care, including the integrated
chronic care approach and the establishment of ward-
based teams of CHWs. DKK is also one of 11 districts
where national health insurance is being phased in over
a 14-year period [46]. DKK comprises four sub-districts,
with a population of 796,823 [41]. The main economic
activities are mining and agriculture. Public health facilities
include regional hospitals, primary health care facilities and
one specialist in-patient mental health facility.
Interventions
Control arm: the integrated chronic care approach imple-
mented by the Department of Health (described in the
introduction) forms the control comparison and has been
implemented in both intervention and control clinics in
the year prior to the introduction of the study intervention
with various levels of technical support provided by the
Department of Health. At facility level the main interven-
tions have been the re-organisation of chronic care ser-
vices and training of clinic staff in PC101. Queues,
appointment systems and waiting rooms for communic-
able disease services (HIV, TB once the intensive phase of
treatment has been completed) have been integrated with
services catering for NCDs and mental health, resulting in
a single chronic care service aimed at reducing fragmenta-
tion and promoting integrated care [47]. Nurses in the
control facilities are able to refer patients identified as having
depression to PHC physicians for the initiation of antide-
pressants (as they are not authorised to prescribe anti-
depressant medications in South Africa); as well as to
mental health specialists. The latter are, however, limited
with only two district-level PHC psychologists available to
service all PHC facilities in the DKK District. Limited
specialist psychological and psychiatric care is also available
at the district hospital.
Intervention arm: in the intervention clinics, we strength-
ened the training of PHC nurse clinicians in the identifica-
tion and management of depression through training in
clinical communication skills and supplementary PC101
mental health sessions (see Additional file 3 of web-based
supplementary material for examples of PC101 guidelines).
We trained facility trainers in the intervention facilities to
deliver this supplementary training material. Facility-based
Fig. 1 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Figure
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trainers in the control facilities are not exposed to this
training in the delivery of this supplementary material. In
addition, we strengthened referral pathways for treatment
and counselling (see the stepped-up collaborative-care
model depicted in Fig. 3). For treatment, we provided sup-
plementary training in mental health care for PHC physi-
cians. For counselling, we introduced lay behavioural health
counsellors into the intervention clinics, with structured
supervision from the project psychologist and district-based
psychologists that includes individual and weekly group
supervision. A comparison of the training provided in the
control and intervention clinics is contained in Table 2.
The intervention coordinator is responsible for monitoring
the intervention to ensure that each component is func-
tioning optimally at the facility level. A detailed monthly
monitoring document was developed and is used to monitor
coverage of nurse training in the supplementary material
given high nurse turnover, nurse referrals to counsellors and
counsellor integration within the facility.
Clinic participants
We considered all 60 public sector primary care clinics in
the DKK District for enrolment in the trial and excluded
clinics if they were mobile or satellite units, saw fewer
than 10,000 attendances per year, or participated in the
piloting of the intervention or data collection. We enrolled
the largest 20 eligible clinics in the trial.
Randomisation, blinding and allocation concealment
We randomised clinics, their staff and patients to one
of two parallel groups, with equal numbers of clinics
(n = 10) in each group, arranging clinics into two
strata determined by their sub-district to avoid
potential confounding resulting from geographically
determined differences in sub-district management.
Twelve clinics serving the central Matlosana sub-
district comprised one strata, and eight more rurally
situated clinics from the Tlokwe, Maquassi Hills and
Ventersdorp sub-districts the second stratum. We rando-
mised clinics in each stratum on a 1:1 ratio yielding
10 clinics per group. Randomisation was completed
using nQuery Advisor by the trial statistician inde-
pendently of the managers who gave permission for
the trial, and before implementation of the interven-
tion or patient recruitment to ensure allocation
concealment.
Intervention clinic staff cannot be blinded to the
clinic’s treatment status given that they have to agree to
additional training activities over and above the standard
PC101 training; as well as the introduction of behav-
ioural health counsellors. Although the outcome assessors
(the fieldworkers) are not informed as to which clinics are
in the intervention arm and which are in the control arm,
it is not possible to guarantee complete blinding of the
fieldworkers given the abovementioned intervention activ-
ities at the intervention clinics. To minimise the potential
for bias, all patient screening, recruitment, interviewing,
follow-up and quality assurance procedures are standar-
dised across both arms to ensure that these data collection
activities and procedures are applied equally in all clinics.
The data collection team also operates independently of
the intervention team, so as to limit exposure to the
intervention.
Fig. 2 Location of the Dr. Kenneth Kaunda and Bojanala Districts in relation to South Africa
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Patient participants
We recruit patient participants from the ambulatory pri-
mary care population attending chronic care services at the
trial clinics. Participants are considered to be eligible for the
trial if they are aged 18 years or older, report receiving treat-
ment for hypertension and screen positive for depression
with a total score of 9 or more on the (PHQ-9) [48] (see
Fig. 4). We chose the PHQ-9 given that it has been
commonly used in other trials on depression [42, 49–51],
and is relatively short and easy to train fieldworkers to ad-
minister. Most importantly, it has also been validated on
the target population in South Africa [52]. We did consider
other depression measures such as the Hamilton Rating
Scale for Depression (HAM-D). The HAM-D, however,
can take up to 15 to 30 min to administer, is ideally
clinician administered and is also complicated to score,
requiring substantial training in getting reasonable inter-
rater agreement [53]. Given that this is a pragmatic trial,
our preference was to use a measure that could be relatively
easier to administer and which had been validated in the
population of interest. The PHQ-9 is aligned with the
Diagnostic and Statistical Manual of Mental Disorders-
Text Revision (DSM-IV-TR) diagnostic criteria for major
depressive disorder and the cut-off of 9 has been deter-
mined for the study population in a preliminary validation
study involving 676 chronic care patients also from the
DKK District. A cut-off of 9 and above was shown through
the validation study to be the optimal cut-off for sensitivity
and specificity indices against the ‘gold standard’ of a
Structured Clinical Interview for a DSM-IV (SCID) diag-
nosis of major depression [51]. The trials findings will,
therefore, apply to patients with major depressive symp-
toms at baseline. In this validation study, performance of a
Setswana translation of the PHQ-9 with an adapted
response to improve understanding of the time period
when symptoms were experienced was compared against
a structured clinical interview administered by a clinical
psychologist [52] (see Table 3 for a comparison of the
original and localised validated version). Mean PHQ-9
scores at baseline will be compared between intervention
Fig. 3 Collaborative-care package for depression
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Table 2 Comparison of training provided to control and intervention clinics
Provider Role Training Content of training Method and timeframe
Control and intervention facilities
PHC nurses Identifies,
provides
brief
interventions
and refers
Basic onsite
PC101 training
Case scenarios used for training in
the identification and management
of common chronic diseases, including
communicable diseases, NCDs (including
hypertension), women’s health and mental
health. Mental health components draw on
the WHO’s mhGAP guidelines [67] and adopt
a syndromic approach to mental health
symptoms (such as stress, insomnia, suicidal
thinking) with diagnostic algorithms and
treatment checklists for depression
(1) PC101 master trainers train facility
trainers who train PHC nurses at
the facilities
(2) 12 weekly sessions over 12 weeks
at facilities (2 of which are on
mental disorders)
(3) Training uses case-scenario material
of patients with chronic conditions,
including co-morbid conditions
Intervention
facilities
PHC nurses Identifies,
provides
brief
interventions
and refers
Orientation
and clinical
communication
skills training
(1) Overview of the system changes being
made by the DoH in South Africa to
accommodate the demands of integrated
chronic care; their role as case managers
within the collaborative-care
model for depression
4 2-h interactive workshops at PHC
facilities/regional training centre
(2) Orientation to patient-centred care and
clinical communication skills necessary
to implement patient-centred care
(3) Skills to manage patient emotions within
the consultation; self-care including how
to cope with their own emotions and
burn-out
(4) Motivational interviewing skills to promote
patient self-management
PC101
supplementary
training in
mental health
(1) Detection of depression and anxiety,
psychoeducation and referral to counsellors
and/or physician for consideration of
psychotropic medication in the case of
moderate to severe depression
(1) PC101 master trainers train facility
trainers (2-day workshop) who train
PHC nurses at the facilities
(2) Detection of risky alcohol use and brief
intervention for harmful/hazardous drinking
and for detoxification and referral to specialist
rehabilitation programmes for dependency
as per the mhGAP guidelines [68]
(2) 3 weekly sessions over 3 weeks at
facilities, with an additional follow-up
session 1 month later
(3) Assessment of suicide intent
(4) Patient review after 8 weeks to assess
response to treatment and onward referral
for specialist care as indicated by the mhGAP
evidence-based guidelines for LMICs [68] if
necessary following a treatment-to-target
approach as contained in the collaborative-care
model (see Fig. 3). Treatment to target involves
tracking a patient’s symptom severity and
adjusting or intensifying treatment should
patients not show an improvement in
symptoms following initial treatment [69]
(3) Training uses case scenarios
case scenario material of chronic
patients with co-morbid mental
disorders
PHC physicians Diagnoses,
initiates
and monitors
response to
psychotropic
medication
Orientation
and training in
mhGAP/PC101
(1) Orientation to the importance of treating
co-morbid depression
3 1-day workshops spread over
6 months
(2) Training in mhGAP guidelines
(3) Follow-up using case studies of patients
Behavioural
health
counsellors
Provides
evidence-based
counselling
Counselling
training
(1) Manualised counselling package comprising 8
sessions (delivered individually or in groups)
1 week of off-site training; 1 week
of peer-to-peer mentoring; in-vivo
supervision by a psychologist of
each session; weekly follow-up group
supervisory sessions, augmented
(2) Session 1: psychoeducation session on depression;
the last session is a closure session; sessions 2-7
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and control arms to assess for any difference which could
indicate potential selection bias. We exclude participants
if they are in need of urgent medical attention, too ill to
provide informed consent or plan to move outside the
vicinity of the clinic during the 12 month follow-up period
(see Fig. 4). We expect some patients to meet eligibility
criteria for both pairs of trials owing to the growing overlap
between HIV and hypertension, recognise that it is
important to represent this co-morbidity within the trials,
and so invite such patients to participate in both trials.
We will enrol roughly equal numbers of depressed
hypertensive patients into the study using the PHQ-9,
across the 20 clinics with a target of 50 participants per
clinic, making up a total of over 1000 participants with
over 500 in each arm (see Fig. 4).
Patient screening and recruitment
In the intervention clinics, we recruit patients following
training of nurses and counsellors in the intervention as
well as a 2-month embedding period. Trained fieldworkers
enrol participants in the study independent of clinical care
or participation in the counselling intervention for depres-
sion. Screening follows a three-stage process:
1. Trained fieldworkers (recruiters) will explain the
study to patients seated in the chronic care clinic
waiting room and invite them to participate. No
mention of depression or hypertension is made at
this stage to avoid possible stigma being attached
to patients who identify themselves as interested.
Fieldworkers then ask these patients one-on-one
whether they are receiving hypertension treatment
and if they plan to reside in the area for the next
12 months.
2. Fieldworkers then escort patients who respond
positively to both these questions to another
fieldworker, trained to perform the interview,
located in a private space in the clinic. The
interviewers brief potential participants about
the psychological content of the questions in the
PHQ-9 and obtain verbal consent before
continuing (this pre-consent process is contained
in Additional file 4 of web-based supplementary
files). Patients who score 9 or more on the PHQ-9
are then taken through the detailed information
sheet and asked to provide written informed
consent (see Additional file 5 of the web-based
supplementary files for more
detail). We collect patient identifiers only once
written consent is provided. We consider this
opt-out verbal consent process necessary to balance
the risks associated with the emotional content of
the screening questions and the practicalities of
Table 2 Comparison of training provided to control and intervention clinics (Continued)
Provider Role Training Content of training Method and timeframe
where possible by weekly individual
supervision sessions
draw on problem solving and cognitive
behavioural techniques, including behavioural
activation to address the common triggers of
depression and anxiety which, in this population,
include poverty, interpersonal conflict, social
isolation and avoidance, grief and loss, and stigma
that emerged from qualitative interviews held
with service users with depression during the
formative phase of the PRIME project in South
Africa in 2 provinces [70]. A prototype had
been field tested in KwaZulu-Natal and positive
results demonstrated in an individually
randomised pilot trial [42, 71]; adherence session
provides information on the chronic condition/s
and chronic medication/s the patients may have
as well as helping patients with adherence
difficulties
(3) While developed to treat depression, the
intervention has been found to promote
improvements in global psychological
functioning as well [42, 71], thus having
the potential for trans-diagnostic effects,
in line with evidence that diagnosis-specific
cognitive-behavioural therapy has beneficial
effects on untargeted co-morbid emotional
disorders [72]
Specialists
(psychologist/
psychiatrist)
Training,
supervision
of counsellors
Orientation to
task sharing
Psychologists (including interns and community
service psychologists) orientated to their roles
One-off workshops
NCD noncommunicable diseases, PHC primary health care, WHO World Health Organisation
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administering written consent to many thousands of
patients, as preliminary work in the district indicated
that we could expect around 12% of patients to screen
positive for depression using the PHQ-9.
3. We collect participant identifiers only once
written consent is provided, and request national
identity numbers to assist linkage with the national
population register, which records deaths in SA.
We ask illiterate participants to confirm that they
have understood each consent line and mark a
cross (x) in each consent line which an independent
witness then witnesses and countersigns.
If patients show signs of suicidality through a positive
response to the suicidal question of the PHQ-9, we
repeat the question to confirm the response. We give
patients who report having suicidal thoughts in the past
2 weeks psychoeducational material on suicidal thoughts
and contact information about where to get help. We
refer patients with suicidal thoughts on more than 7
days in the past 2 weeks to the nurse on the same day
for assessment and onward referral if necessary.
Data collection and outcome measures
Participants provide written consent before completing
the full baseline questionnaire in the language of their
choice, predominantly Setswana although some interviews
are also conducted in Afrikaans or English. This question-
naire includes items on demographics and multiple instru-
ments (outlined below, Table 4) (see Additional file 6 of
Fig. 4 Flow of participants
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supplementary files for full questionnaire). Anthropomet-
ric measurements include height, weight, waist circumfer-
ence and blood pressure. Trained fieldworkers measure
the latter using a digital sphygmomanometer, and take
readings while the participant is seated at three time
points during the course of the interview. We use the
‘Averaging Rules for Determining Mean Blood Pressure’
from the National Health and Nutrition Examination
Survey (NHANES) Health Technology/Blood Pressure Pro-
cedures Manual [54] to determine the average blood pres-
sure whereby the first measurement is discarded and the
second two readings used to calculate a mean blood pres-
sure for each assessment (baseline, 6 months, 12 months).
The primary outcome measure is a reduction in PHQ-
9 score of 50% or more compared with baseline [49–51,
55, 56], evaluated at 6 months. Thus, we use the PHQ-9
to determine eligibility for the trial as well as to measure
mental health outcomes at 6 and 12 months.
Secondary outcomes (see Table 4) include: (1) response
at 12 months defined as a 50% reduction in the score on
the PHQ-9, (2) remission at 12 months defined as a score
of < 5 on the PHQ-9, (3) mean PHQ-9 scores at 6 and 12
months, (4) antidepressant treatment, including initiation
or intensification of antidepressant medication, (5) referral
to a counsellor for depression counselling, (6) referral to a
mental health specialist (clinical psychologist, psychiatrist
or secondary care services), (7) blood pressure at 6 and 12
months, (8) disability measured at 12 months using the
WHO Disability Assessment Schedule version 2.0 (WHO-
DAS 2), (9) stress symptoms measured at 12 months using
the Perceived Stress Scale (PSS), (10) patient assessment
of quality of chronic illness care received measured at 12
months using the Patient Assessment of Care for Chronic
Conditions (PACIC) scale, (11) health care utilisation in-
cluding clinic visits and hospital admissions, (12) resource
use and economic outcomes measured using a Service
Use Questionnaire and (13) all-cause mortality measured
through follow-up at the clinic and linkage to the South
African population register.
We obtain demographic information through self-report
at baseline, including questions on sex, age, educational
and employment status, income and household compos-
ition. We repeat some of the questions at 6- and 12-
month interviews to track changes in economic status.
The WHODAS 2 [57] is a generic assessment instru-
ment for disability for diseases including mental disorders.
We use the 12-item interviewer administered version
which has been previously used on a South African ART
patient population [58].
The Perceived Stress Measure (PSS) [59] is a 10-item
self-reported measure that provides an assessment of the
extent to which situations in a person’s life are appraised
Table 3 Patient Health Questionnaire-9: general and localised versions
Over the last 2 weeks, how often have you been bothered by any of the following
problems?a
Not at all Several days More than half
of the days
Nearly
every day
Over the last 2 weeks, how often have you been bothered by any of the following
problems?b
0 days 1–7 days 8–11 days 12–14 days
Little interest or pleasure in doing things 0 1 2 3
Feeling down, depressed, or hopeless 0 1 2 3
Trouble falling or staying asleep, or sleeping too much 0 1 2 3
Feeling tired or having little energy 0 1 2 3
Poor appetite or overeating 0 1 2 3
Feeling bad about yourself – or that you are a failure or have let yourself or your
family down
0 1 2 3
Trouble concentrating on things, such as reading the newspaper or watching
television
0 1 2 3
Moving or speaking so slowly that other people could have noticed? Or the
opposite - being so fidgety or restless that you have been moving around a
lot more than usual
0 1 2 3
Thoughts that you would be better off dead or of hurting yourself in some way 0 1 2 3
Please could you confirm your answer for this question: Over the last 2 weeks,
how often have you been bothered by thoughts that you would be better off
dead or of hurting yourself in some way
0 1 2 3
Total score ___ = ___ + ___ + ___
If you checked off any problems, how difficult have these problems made it
for you to do your work, take care of things at home, or get along with other
people?a, b
Not difficult
at all
Somewhat
difficult
Very
difficult
Extremely
difficult
aGeneral version
bLocalised version
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Table 4 Schema of patient-level data collection
Outcome
Baseline 6 months 12 months
Outcome Measurement Source Metric
Primary measurements
Depression symptoms PHQ-9 Self-reported 50% reduction in
PHQ-9 score
●a ●●b ●
Secondary mental health
outcomes
Depression symptoms PHQ-9 Self- reported 50% reduction in
PHQ-9 score
● ● ●●
Depression symptoms PHQ-9 Self- reported Remission defined
as score of < 5 on
PHQ-9
● ● ●●
Depression symptoms PHQ-9 Self- reported Mean PHQ-9 scores
at 6 and 12 months
● ●● ●●
Antidepressant treatment Self- reported Proportion with
antidepressant
treatment initiated
or intensified
● ● ●●
Counselling Self- reported Proportion receiving
counselling by
clinic-based
counsellor
● ● ●●
Referral to specialist
mental health
worker/service
Self- reported Proportion referred ● ● ●●
Stress Perceived
Stress Scale
Self-reported Mean score ● ●●
Secondary hypertensive
outcomes
Blood pressure Interviewer
measured
Difference in means ● ●● ●●
Retention in care Self-reported;
clinic records
Proportion in care ● ●●
Integrated care
outcomes
Cardiovascular
risk factors
Blood pressure,
weight, Body
Mass Index, waist
circumference
Interviewer
measured
Difference in means ● ● ●●
Diagnosis of other
co-morbid illnesses
Self-reported Proportion diagnosed ●●
Quality of chronic
illness care received
Patient Assessment
of Care for Chronic
Conditions (PACIC)
Self-reported Mean PACIC score ● ●●
Health economic
outcomes
Health care
utilisation
Self- reported;
linkage with
hospitalisation
databases
Incidence rate ratio ● ●●
Productivity and
economic outcomes
Self- reported ● ●●
Disability WHO Disability
Assessment
Schedule 2.0
Self- reported Mean score ● ●●
Safety measurements
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as stressful. It has been previously used in South Africa
with perceptions of high levels of stress associated with
higher risk for developing some mental disorders [60].
The Patient Assessment of Care for Chronic Conditions
(PACIC) scale is a self-reported measure of quality of
patient-centred chronic clinical services received in the
past 6 months, which emphasises self-management sup-
port in the form of collaborative goal setting, problem-
solving and follow-up [61]. The original 20-item scale was
adapted for the local context and reduced to 10 items.
Limitations
Limitations of the trial design include dependence on self-
reporting of hypertensive medication for inclusion in the
trial, lack of detailed information on prescribed medication
for hypertension, and limited data on adherence to medica-
tion. While the broad inclusion criteria and light-touch
follow-up are consistent with the pragmatic design and are
intended to maximise generalisability to an intervention in
real-world circumstances, it can be difficult to assess
whether all the study participants were eligible for the inter-
vention and to quantify the processes of care in a causal
pathway. A qualitative process evaluation will be conducted
alongside the RCT to address these gaps and to understand
how integrating mental health services for depression
affects care of physical conditions like hypertension.
Data management
Fieldworkers use handheld devices to collect data that is
uploaded onto a secure server. The Trial Management
Team manage data quality assurance through weekly tele-
phonic data meetings when uploaded data is reviewed, as
well as bimonthly face-to-face meetings of the Data
Management Team comprising the data manager, principal
investigators (PIs) and invited co-investigators, including
the statistician depending on the need. Data is collected
alongside the first phase of the CobALT trial in the DKK
District, and is subject to the same standard operating
procedures for data management for the CobALT trial.
These include intensive fieldworker training in the adminis-
tration of the interview, and onsite supervision by three
fieldwork supervisors who perform daily quality checks on
interviews conducted, observe interviews weekly to ensure
the interviewer administers the questionnaire and performs
the measurements as trained, and assists in addressing
fieldwork problems that may have impeded data collection.
Patients receive a ZAR50 voucher (just under US$3) in
appreciation for their time. We schedule follow-up
appointments for 6 and 12 months at the clinic, with
reminders and confirmation of follow-up interviews
provided using text messaging and, where appropriate,
telephone calls.
Sample size and power calculations
We calculated sample size on the following assumptions:
we considered the primary outcome as the proportion of
respondents considered to have at least a 50% reduction in
PHQ-9 scores at 6 months compared with baseline; an
intraclass correlation coefficient (ICC) of 0.04 for this out-
come and is based on a similar trial in a LIMC setting [62],
a significance level of 0.05; and loss to follow-up of 15% to
make provision for patients who may leave the area, die or
refuse to take part in the study at follow-up. This loss-to-
follow-up rate was determined on the basis of a previous
trial in South Africa involving chronic care patients, includ-
ing those with depression [63]. The trial statistician calcu-
lated a sample size comprising 50 patients in each of the 20
facilities making up 1000 patients (500 patients in the inter-
vention arm and 500 patients in the control arm) to provide
90% power to detect an effect size of 17% (60% control
versus 77% intervention), and 80% power to detect an effect
size of 15% (60% control versus 75% intervention).
Statistical methods
We will analyse data using the STATA statistical package
and will blind all analysis pertaining to the primary and
Table 4 Schema of patient-level data collection (Continued)
Outcome
Baseline 6 months 12 months
Outcome Measurement Source Metric
Hospitalisation Self- reported;
linkage with
hospitalisation
databases
Proportion hospitalised ● ● ●●
All-cause mortality Clinic, report,
linkage with
mortality register
Proportion who died ● ● ●●
Suicide Follow-up of cause
of all known deaths
with clinic and
family interview
Proportion of suicides ● ● ●●
a● data measured
b●● time when endpoint for outcome will be reported
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secondary objectives until the analysis is finalised. At
baseline, we will calculate descriptive statistics including
frequencies, means and standard deviations on both the
intervention and control arms to establish comparability
of the arms. For the intention-to-treat analysis of the
primary outcome, we will use binomial regression to
estimate differences in proportions of participants
considered having at least 50% reduction in depressive
symptoms, as measured using PHQ-9 at 6 months. We
will take into account the clustering of participants
within facilities for any inference done. We will complete
secondary analyses whereby we adjust for baseline PHQ-
9 scores, and will test for interaction effects between
physical conditions. Secondary analysis will also include
a comparison of outcomes in intervention-group partici-
pants who did and did not receive the intervention with
adjustment for baseline covariates; as well as sub-group
analysis of blood pressure outcomes in patients who had
uncontrolled blood pressure at baseline.
Process evaluation
The UK MRC framework for the process evaluation of
complex evaluations [64] informs the process evaluation
design. We have adopted a mixed-methods approach that
combines quantitative process variables collected during
the 12-month period of the trial and post hoc in-depth
qualitative process evaluation interviews across the clusters
that follow analysis of the trial outcome data. Through
monitoring changes at a facility and district level on a regu-
lar basis, we will gather information related to contextual
factors that may influence outcomes in the intervention
and control clusters. To monitor fidelity and quality of
implementation we will collect (1) process indicators on
coverage of training sessions and supervision received
across the intervention clusters for PHC providers and
behavioural health counsellors, (2) data on the total number
of patients identified and referred for treatment of depres-
sion, and (3) fidelity checks of the counselling implementa-
tion through analysing audio-recordings of counselling
sessions. We will employ in-depth qualitative process evalu-
ation interviews to examine variations in the trial outcomes
associated with potential causal mechanisms and contextual
factors. These interviews will be informed by the 6-month
depression primary outcome data, and conducted post hoc
on purposefully sampled clusters and individuals to under-
stand variations in the clusters that may emerge in the out-
come data and analysed using thematic analysis [65].
Ethical considerations
In order to protect the confidentiality of the information
provided by research participants, the research team,
including fieldworkers, are required to sign a confidentiality
agreement. The hand-held data collection devices are also
password protected and data from interviews are uploaded
immediately onto a secure server which is permission and
access controlled, at which point they are erased from the
hand-held device. Access to the uploaded data is restricted
to the PIs, data manager, data architect, site project coord-
inator and research manager. All data collected will also be
anonymised for analysis purposes.
Monitoring of adverse events
The Data and Safety Monitoring Board (DSMB) for the
COBALT trial also provides safety monitoring for the
PRIME-SA trial. Specific adverse events, applicable to the
PRIME-SA trial, and protocols for management and report-
ing are specified in a DSMB Charter and are detailed in
Table 5. Of note, given the high rate of positive responses
to the ninth item of the PHQ-9 (‘Thoughts that you would
be better off dead or of hurting yourself in some way’)
during the past 2 weeks in the formative PRIME work, and
a low rate of reported deaths by suicide in the North West
Province, the DSMB advised against over-interpretation of
a single item in a questionnaire. We thus introduced a
standard operating procedure previously described that
distinguishes patients needing psychoeducation, where
patients are provided with information on their condition
and where to get help from local community resources and
helplines, from those requiring immediate assessment by
the clinic nurse and onward referral. Death is identified
during the follow-up periods and the cause of death investi-
gated by the fieldworkers through contacting the family
and through reviewing the clinic files and the National
Death Registry. Death by suicide is considered a serious
adverse event as it could be associated with the intervention
and is reported to the COBALT DSMB and UKZN BREC
within 7 days of knowledge of confirmed suicide.
Further, while hospitalisation, prolonged hospitalisation
and death would normally be considered serious adverse
events, these events are expected to occur fairly frequently
among the participant population given that they all suffer
from hypertension which may also be co-morbid with
other chronic conditions, thus increasing their vulnerability
to hospitalisation and premature death. We thus monitor
hospitalisations and deaths at 6- and 12-month follow-up
interviews as well as link hospitalisation data on a quarterly
basis, with a once-off linkage with the national population
register being planned as well. The frequency of these
events are reviewed at the 6-monthly DSMB meetings,
which are then reported to the relevant Institutional Review
Board (UKZN) with the DSMB Letter of Recommendation.
Dissemination
The PIs have established a Trial Steering Committee
comprising key national, provincial and district stake-
holders including policy-makers, planners and managers
(see Additional file 1 supplementary web-based material
for more detail) where trial progress is being reported
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and provides a platform to disseminate the trial results
and partake in discussions around policy implications.
These stakeholders have expressed their commitment to
implementing the intervention package should the trial
results be successful. Scale-up would require, inter alia,
the expansion of the PC101 training to include clinical
communication skills; a dedicated mental health module;
and role clarification of the lay behavioural health coun-
sellors within the collaborative-care model.
Further, the results of the trial will be written up in a
main outcome publication within a year of the finalisation
of the fieldwork, together with additional papers detailing
secondary outcomes and sub-group analyses. Authorship
will be determined on the basis of contributions made to
the design, intervention, data collection and analysis.
Discussion
In the context of the rising burden of NCDs in LMICs,
and CVD specifically in South Africa, the high prevalence
of co-morbid depression is a major and growing public
health threat. It interferes with treatment adherence as
well as health-enhancing lifestyle changes, and has the
potential to undermine investments in health care for
these conditions. There is an urgent need to close the
treatment gap for common mental disorders in LMICs
and South Africa specifically, especially in patients who
Table 5 Defining, monitoring and reporting of harm in the PRIME trial
Type of harm Source and method
of identification
Action(s) to mitigate harm
to specific participants
Reporting frequency and to whom
Adverse events
Positive response to ninth item of the
PHQ-9: ‘Thoughts that you would be
better off dead or of hurting yourself
in some way’
Participant interviews
(baseline, 6 month
follow-up, 12 month
follow-up).
Flag within electronic
questionnaire prompting
interviewer to act
Repeat question to reduce
telescoping-type reporting errors.
If ≥ 8 days in last 2 weeks,
immediate referral to clinic staff.
If between 1 and 7 days then
written educational material given
6-monthly report to DSMB
6-monthly to IRB (with DSMB
letter of recommendation)
PHQ-9 score of ≥ 20 at 12 months
suggesting persistent severe
depression
Participant interviews
(12-month follow-up).
Data report (monthly)
Summary forwarded to clinic
together with recommendations
for further treatment
6-monthly report to DSMB
6-monthly to IRB (with DSMB
letter of recommendation)
Blood pressure severely raised
(≥ 180/110) placing participant
at immediate risk of cardiovascular event
Participant interviews
(baseline, 6-month
follow-up, 12-month
follow-up).
Flag within electronic
questionnaire prompting
interviewer to act
Immediate referral to clinic
staff for review
6-monthly report to DSMB
6-monthly to IRB (with DSMB
letter of recommendation)
Raised blood pressure at
follow-up representing
undiagnosed or uncontrolled
hypertension
Participant interviews
(baseline, 6-month
follow-up, 12-month
follow-up).
Longitudinal patient
record
Summary forwarded to clinic
together with recommendations
for further treatment
6-monthly report to DSMB
6-monthly to IRB (with DSMB
letter of recommendation)
Serious adverse events
Hospitalisation Participant interviews
(baseline, 6-month
follow-up, 12-month
follow-up).
Routinely collected
hospitalisation data.
Data report (monthly).
No immediate action other
than 6-monthly review by DSMB
6-monthly report to DSMB
6-monthly to IRB (with DSMB
letter of recommendation)
Death (excluding suicide) Participant interviews
(Loss to Follow-up Form).
National Population Register.
Data report (monthly)
No immediate action other than
6-monthly review by DSMB
6-monthly report to DSMB
6-monthly to IRB (with DSMB
letter of recommendation)
Death by suicide Participant interviews
(Loss to Follow-up Form).
National Population Register
(providing we are able to
access cause of death).
Data report (weekly)
Immediate notification of PI (LF)
who will follow-up with fieldwork
staff to confirm suicide and
establish date of suicide
Notification of IRB, DSMB and
NIMH within 7 days of knowledge
of confirmed suicide
DSMB Data and Safety Monitoring Board, IRB Institutional Review Board, PHQ-9 Patient Health Questionnaire-9, PI principal investigator
Petersen et al. Trials  (2018) 19:192 Page 15 of 18
have multiple co-morbid chronic conditions – given the
negative health impacts and economic costs. It is particu-
larly important to know whether such an intervention
leads to cost saving both to the health care system
(through improved physical health outcomes and reduced
health care utilisation) and broader society (through
improved functioning, productivity and income).
Given the paucity of mental health specialists in
LMICs, task sharing has been recommended as a strategy
to close this gap globally as well as locally in South Africa
[66, 67]. PRIME in South Africa, in collaboration with the
Department of Health has developed a collaborative-
team-based package for depression care in the chronic
care population that strengthens and builds on existing
task-sharing strategies. The need for this RCT to evaluate
the real-world effectiveness of this integrated collaborative
approach is spurred by the lack of evidence on the effect-
iveness of collaborative-care models on mental and physical
health outcomes in chronic populations in LMICs. The
proposed trial will be the first RCT evaluating the real-
world effectiveness of a task-shared collaborative team ap-
proach to caring for hypertensive patients with co-morbid
depression in a LMIC.
Trial status
At the time of submission (September 2016) the trial is in
follow-up stage. Recruitment and baseline data collection
began in April 2015, and will continue until the end of
October 2016.
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